Valeant Pharmaceuticals International Inc said Executive Vice President Deb Jorn had not been asked to leave, in response to investor queries, a day after the company said she had resigned for personal reasons. Jorn oversaw the Canadian drugmaker's U.S. dermatology business, which had ties with Philidor Rx Services, a specialty pharmacy that used aggressive tactics to increase insurer reimbursement, mostly for dermatology drugs.